Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children.
Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children.
复制标题
DOI：
10.3345/kjp.2017.60.5.151
复制
发表时间：
2017-05
影响因子：
--
通讯作者：
Yu J
中科院分区：
文献类型：
--
作者：
Lee E;Cho HJ;Hong SJ;Lee J;Sung H;Yu J
儿童肺炎支原体对大环内酯类抗生素的耐药率迅速上升。大环内酯类抗生素耐药M.肺炎支原体（MSMP）和大环内酯类耐药-M.肺炎支原体（MRMP）缺乏。本研究的目的是确定M.肺炎支原体感染的韩国儿童。2015年，MSMP和MRMP的临床表现进行了比较。122例0-18岁儿童M.对95例肺炎患儿进行大环内酯类药物敏感试验。通过回顾性病历获得临床表现。M.肺炎支原体肺炎患儿82例（87.2%）;肺炎其中1例为野生型和23 SrRNA A2063 G突变的混合型。肺炎。在我院首次就诊时，MSMP组和MRMP组的临床、实验室和放射学结果无显著差异。MRMP组开始使用大环内酯类药物与退热之间的时间间隔显著延长（4.9±3.3 vs. 2.8±3.1天，P=0.039）。M.肺炎支原体感染儿童的肺炎发病率非常高。肺炎在韩国MRMP的临床表现与MSMP相似，但大环内酯类药物给药后的退热期不同。需要持续监测MRMP的发生和抗菌药物敏感性，以控制其传播并制定治疗二线抗生素耐药M的策略。肺炎感染。
Macrolide resistance rate of Mycoplasma pneumoniae has rapidly increased in children. Studies on the clinical features between macrolide susceptible-M. pneumoniae (MSMP) and macrolide resistant-M. pneumoniae (MRMP) are lacking. The aim of this study was to identify the macrolide resistance rate of M. pneumoniae in Korean children with M. pneumoniae penupmonia in 2015 and compare manifestations between MSMP and MRMP. Among 122 children (0–18 years old) diagnosed with M. pneumoniae pneumonia, 95 children with the results of macrolide sensitivity test were included in this study. Clinical manifestations were acquired using retrospective medical records. The macrolide resistant rate of M. pneumoniae was 87.2% (82 of 94 patients) in children with M. pneumoniae pneumonia. One patient showed a mixed type of wild type and A2063G mutation in 23S rRNA of M. pneumoniae. There were no significant differences in clinical, laboratory, and radiologic findings between the MSMP and MRMP groups at the first visit to our hospital. The time interval between initiation of macrolide and defervescence was significantly longer in the MRMP group (4.9±3.3 vs. 2.8±3.1 days, P=0.039). The macrolide resistant rate of M. pneumoniae is very high in children with M. pneumoniae pneumonia in Korea. The clinical manifestations of MRMP are similar to MSMP except for the defervescence period after administration of macrolide. Continuous monitoring of the occurrence and antimicrobial susceptibility of MRMP is required to control its spread and establish strategies for treating second-line antibiotic resistant M. pneumoniae infection.